ArticleObesity pillars2024
Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes.
Article in Obesity pillars, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 4 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.Obesity surgery · 2025Pooled it
- Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.Obesity surgery · 2025Pooled it
- Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan.Obesity pillars · 2026Article
- Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.Obesity pillars · 2026Review
- Vitamin B12 toxicity secondary to post-bariatric supplementation: a case report on presentation and literature review.International journal of surgery case reports · 2026Article
- Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity.Nutrients · 2026Review
- Improved cardiometabolic outcomes after laparoscopic sleeve gastrectomy in a heart transplant patient; a case report.BMC cardiovascular disorders · 2025Article
- GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study.Saudi medical journal · 2025Article
- Severe lumbosacral polyradiculopathy secondary to micronutrient deficiencies in a patient on semaglutide therapy following bariatric surgery.Endocrinology, diabetes & metabolism case reports · 2025Article
- The Interplay Between Psychological and Neurobiological Predictors of Weight Regain: A Narrative Review.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucagon-like peptide (GLP)-1 analogue may be useful for controlling weight recurrence and diabetes relapse after bariatric surgery, but may also adversely affect the measured nutritional metrics. This study aimed to investigate the effect of treatment with once-weekly semaglutide after laparoscopic sleeve gastrectomy (LSG) in patients with type 2 diabetes (T2D). We also examined the effects of combined use with a low-energy, high-protein formula diet (FD). Methods: This study was a single-center retrospective database analysis. We enrolled 29 Japanese patients with T2D who underwent LSG, and more than 12 months later received semaglutide. The patients were divided retrospectively into a FD group (=6) and a conventional diet (CD) group (n = 23). Results: BMI and HbA1c decreased significantly by 10.7 kg/m Conclusion: Semaglutide after LSG in patients with obesity and T2D resulted in additional weight reduction and improved glycemic control, but worsened measured nutritional metrics. Administration of a low-energy, high protein formula diet may ameliorate adverse nutritional effects of semaglutide in patients with T2D after LSG. (Ethics Committee of Toho University Sakura Medical Center approval number S18061).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.